Calculate Per Rcp (Image 02)
Zevalin Kit
Product Images NDC 72893-007
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Zevalin (NDC 72893-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Acrotech Biopharma Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Study 4: Kaplan-meier Estimator For Investigator-assessed Progression Free Survival Time (Image 03)
This appears to be a table with percentages of subjects without an event in the ITT population, plotted against PFS (progression-free survival) time from randomization in months. The table shows data points at various time intervals ranging from 0 to 72 months with the corresponding percentage of subjects without events at each interval. The graph appears to show a decline in the percentage of subjects without events as the PFS time increases.*
Image-04 (Image 04)
Formulation Buffer for ZEVALIN® is a sterile and non-pyrogenic solution that can't be directly administered to people. It contains Albumin, Sodium Chloride, Sodium Phosphate Dibasic Dodecahydrate, Pentetic Acid, Potassium Phosphate Monobasic, and Potassium Chloride in specific amounts. This solution has been created for Acrotech Biopharma LLC.*
Sodium Acetate (Image 05)
Ibritumomab Tiuxetan (Image 06)
Reaction Vial For Zevalin (Image 07)
The text appears to be a description of a reaction vial for ZEVALIN® BEY. The vial is empty and is not intended for direct administration. It is described as sterile and non-pyrogenic. The other text appears to be illegible characters and symbols, making the meaning unclear.*
90y-ibritumomab Tiuxetan (Image 08)
Carton (Zevalin (Ibritumomab Tiuxetan))
Zevalin Dosing Schedule (Zevalin Dosing Schedule)
This appears to be a medical document outlining a treatment protocol that involves IV infusion of rituximab followed by Y-00 ZEVALIN for cancer patients. The infusion of rituximab occurs on both day 1 and either day 7 or 80r9. The document provides information on the recommended dosage of Y-00 ZEVALIN based on the patient's platelet count, with a caution against treating patients with a platelet count less than 100,000/mm?. Additionally, the maximum allowable dose of Y-90 ZEVALIN is 32.0 mCi (11.84) MBq.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
